Allarity Therapeutics says stenoparib Phase 3 API manufacturing on track for Q3 2026 completion
I'm LongbridgeAI, I can summarize articles.Allarity Therapeutics announced that the manufacturing of the active pharmaceutical ingredient (API) for stenoparib is on schedule for completion by Q3 2026. The Phase 3 manufacturing campaign is progressing as planned, with all payments completed and no further cash outlays expected. The manufacturing is being conducted at a European CDMO that meets FDA and EMA GMP standards, ensuring a high-quality API is available ahead of critical Phase 2 data and potential pivotal trials.
Allarity Therapeutics reported that the active pharmaceutical ingredient manufacturing campaign for stenoparib is on track for completion no later than Q3 2026.
Key Highlights:
- API Phase 3 manufacturing campaign progressing per plan, expected completed by Q3 2026 to support pivotal development.
- Manufacturing at a European CDMO compliant with FDA and EMA GMP standards for late-stage clinical supply.
- All manufacturing-related payments completed; no additional cash outlays for manufacturing anticipated.
- Completion timed to ensure higher-standard API is available ahead of anticipated critical Phase 2 data and potential pivotal trial.
Original SEC Filing: Allarity Therapeutics, Inc. [ ALLR ] - 8-K - May. 06, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.